Pfizer Inc. (NYSE:PFE) Shares Purchased by Tang Capital Management LLC

Tang Capital Management LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 66.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,908 shares of the biopharmaceutical company's stock after buying an additional 17,170 shares during the quarter. Tang Capital Management LLC's holdings in Pfizer were worth $1,138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Thornburg Investment Management Inc. increased its stake in shares of Pfizer by 11.9% during the fourth quarter. Thornburg Investment Management Inc. now owns 9,895,877 shares of the biopharmaceutical company's stock valued at $262,538,000 after buying an additional 1,053,703 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Pfizer by 62.3% during the fourth quarter. Toronto Dominion Bank now owns 4,695,774 shares of the biopharmaceutical company's stock valued at $124,578,000 after purchasing an additional 1,802,005 shares in the last quarter. Sender Co & Partners Inc. lifted its holdings in Pfizer by 29.8% in the fourth quarter. Sender Co & Partners Inc. now owns 11,056 shares of the biopharmaceutical company's stock valued at $293,000 after acquiring an additional 2,535 shares during the period. Sherbrooke Park Advisers LLC bought a new position in Pfizer in the fourth quarter valued at about $1,329,000. Finally, Sig Brokerage LP bought a new position in Pfizer in the fourth quarter valued at about $1,102,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 2.2%

Shares of PFE traded up $0.51 during trading hours on Tuesday, hitting $23.51. The company had a trading volume of 56,982,321 shares, compared to its average volume of 41,026,668. The company's fifty day moving average price is $23.60 and its two-hundred day moving average price is $25.28. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market capitalization of $133.66 billion, a PE ratio of 16.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the business posted $0.82 earnings per share. The firm's revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.32%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.